Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02449616 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Repeat Administration of Purified Poloxamer 188
A Phase 3 study, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT02449616 is a Phase 3 study that has completed, run by Mast Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT02449616, a Phase 3 study, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.
Interventions
- DRUG MST-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02449616
The ClinicalTrials.gov registry entry for NCT02449616 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mast Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MST-188 is the first listed.
NCT02449616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02449616 about?
NCT02449616 is a clinical study titled "Evaluation of Repeat Administration of Purified Poloxamer 188". The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.
What is the current status of trial NCT02449616?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2015-06.
What interventions are being tested in trial NCT02449616?
The interventions under investigation include: MST-188 (DRUG).
Who is sponsoring clinical trial NCT02449616?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.